From: The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Clinical endpoint | DDR deficiency | ICI | Cancer type | Proficiency type | Deficiency type | Refs |
---|---|---|---|---|---|---|
ORR | HR | Nivolumab+ipilimumab | Prostate cancer | 22.6% | 50.0% | [13] |
DDR positive | Nivolumab+ipilimumab | Prostate cancer | 23.1% | 36.4% | [13] | |
DDR positive | ICI | Prostate cancer | 20.0% | 40.0% | [48] | |
MMR | Pembrolizumab | Colorectal cancer | 0.0% | 40.0% | [24] | |
PFS | MMR | Pembrolizumab | Colorectal cancer | 2.2 m | NR | [24] |
OS | MMR | Pembrolizumab | Colorectal cancer | 5.0 m | NR | [24] |
HR | Nivolumab+ipilimumab | Prostate cancer | 19.0 m | NR | [13] |